Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply

N Engl J Med. 2021 May 13;384(19):1871-1872. doi: 10.1056/NEJMc2103465.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antihypertensive Agents / adverse effects
  • Epoprostenol / analogs & derivatives
  • Humans
  • Hypertension, Pulmonary* / drug therapy

Substances

  • Antihypertensive Agents
  • Epoprostenol
  • treprostinil